Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management.
Clinical management4
Ferritin5
Macrophage activation syndrome1
Pathogenesis3
Sepsis2
Journal
Inflammation research : official journal of the European Histamine Research Society ... [et al.]
ISSN: 1420-908X
Titre abrégé: Inflamm Res
Pays: Switzerland
ID NLM: 9508160
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
20
03
2024
accepted:
01
10
2024
revised:
01
08
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
Sepsis represents a significant global health and hygiene challenge. Excessive activation of macrophages in sepsis can result in certain patients displaying characteristics akin to those observed in Macrophage Activation Syndrome (MAS). MAS represents a grave immune system disorder characterized by persistent and severe inflammation within the body. In the context of sepsis, MAS presents atypically, leading some researchers to refer to it as Macrophage Activation-Like Syndrome (MALS). However, there are currently no effective treatment measures for this situation. The purpose of this article is to explore potential treatment methods for sepsis-associated MALS. The objective of this review is to synthesize the specific pathophysiological mechanisms and treatment strategies of MAS to investigate potential therapeutic approaches for sepsis-associated MALS. We searched major databases (including PubMed, Web of Science, and Google Scholar etc.) for literature encompassing macrophage activation syndrome and sepsis up to Mar 2024 and combined with studies found in the reference lists of the included studies. We have synthesized the underlying pathophysiological mechanism of MALS in sepsis, and then summarized the diagnostic criteria and the effects of various treatment modalities utilized in patients with MAS or MALS. In both scenarios, heterogeneous treatment responses resulting from identical treatment approaches were observed. The determination of whether the patient is genuinely experiencing MALS significantly impacts the ultimate outcomes of therapeutic efficacy. In order to tackle this concern, additional clinical trials and research endeavors are imperative.
Sections du résumé
BACKGROUND
BACKGROUND
Sepsis represents a significant global health and hygiene challenge. Excessive activation of macrophages in sepsis can result in certain patients displaying characteristics akin to those observed in Macrophage Activation Syndrome (MAS). MAS represents a grave immune system disorder characterized by persistent and severe inflammation within the body. In the context of sepsis, MAS presents atypically, leading some researchers to refer to it as Macrophage Activation-Like Syndrome (MALS). However, there are currently no effective treatment measures for this situation. The purpose of this article is to explore potential treatment methods for sepsis-associated MALS.
OBJECTIVE
OBJECTIVE
The objective of this review is to synthesize the specific pathophysiological mechanisms and treatment strategies of MAS to investigate potential therapeutic approaches for sepsis-associated MALS.
METHOD
METHODS
We searched major databases (including PubMed, Web of Science, and Google Scholar etc.) for literature encompassing macrophage activation syndrome and sepsis up to Mar 2024 and combined with studies found in the reference lists of the included studies.
CONCLUSION
CONCLUSIONS
We have synthesized the underlying pathophysiological mechanism of MALS in sepsis, and then summarized the diagnostic criteria and the effects of various treatment modalities utilized in patients with MAS or MALS. In both scenarios, heterogeneous treatment responses resulting from identical treatment approaches were observed. The determination of whether the patient is genuinely experiencing MALS significantly impacts the ultimate outcomes of therapeutic efficacy. In order to tackle this concern, additional clinical trials and research endeavors are imperative.
Identifiants
pubmed: 39404874
doi: 10.1007/s00011-024-01957-7
pii: 10.1007/s00011-024-01957-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 81873870（Z-HT)
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Singer M, et al. The Third International Consensus definitions for Sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
pubmed: 26903338
pmcid: 4968574
doi: 10.1001/jama.2016.0287
Rudd KE, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of Disease Study. Lancet. 2020;395(10219):200–11.
pubmed: 31954465
pmcid: 6970225
doi: 10.1016/S0140-6736(19)32989-7
Chiu C, Legrand M. Epidemiology of sepsis and septic shock. Curr Opin Anaesthesiol. 2021;34(2):71–6.
pubmed: 33492864
doi: 10.1097/ACO.0000000000000958
Yao Y, et al. α-Lactose improves the survival of septic mice by blockade of TIM-3 signaling to prevent NKT Cell apoptosis and attenuate cytokine storm. Shock. 2017;47(3):337–45.
pubmed: 27504802
doi: 10.1097/SHK.0000000000000717
Delano MJ, Ward PA. The immune system’s role in sepsis progression, resolution, and long-term outcome. Immunol Rev. 2016;274(1):330–53.
pubmed: 27782333
pmcid: 5111634
doi: 10.1111/imr.12499
Opitz B, et al. Role of toll-like receptors, NOD-like receptors and RIG-I-like receptors in endothelial cells and systemic infections. Thromb Haemost. 2009;102(6):1103–9.
pubmed: 19967140
Faure E, et al. Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. J Biol Chem. 2000;275(15):11058–63.
pubmed: 10753909
doi: 10.1074/jbc.275.15.11058
Colbert JF, Schmidt EP. Endothelial and microcirculatory function and dysfunction in Sepsis. Clin Chest Med. 2016;37(2):263–75.
pubmed: 27229643
pmcid: 4884305
doi: 10.1016/j.ccm.2016.01.009
Mikacenic C, et al. Biomarkers of endothelial activation are Associated with poor outcome in critical illness. PLoS ONE. 2015;10(10):e0141251.
pubmed: 26492036
pmcid: 4619633
doi: 10.1371/journal.pone.0141251
Mostefai HA, et al. Circulating microparticles from patients with septic shock exert protective role in vascular function. Am J Respir Crit Care Med. 2008;178(11):1148–55.
pubmed: 18723433
doi: 10.1164/rccm.200712-1835OC
Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol. 2006;6(3):173–82.
pubmed: 16498448
doi: 10.1038/nri1785
Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006;6(11):813–22.
pubmed: 17039247
doi: 10.1038/nri1943
Delano MJ, et al. Sepsis induces early alterations in innate immunity that impact mortality to secondary infection. J Immunol. 2011;186(1):195–202.
pubmed: 21106855
doi: 10.4049/jimmunol.1002104
Eash KJ, et al. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest. 2010;120(7):2423–31.
pubmed: 20516641
pmcid: 2898597
doi: 10.1172/JCI41649
Grailer JJ, et al. Persistent neutrophil dysfunction and suppression of acute lung injury in mice following cecal ligation and puncture sepsis. J Innate Immun. 2014;6(5):695–705.
pubmed: 24861731
pmcid: 4140989
doi: 10.1159/000362554
Morris AC, et al. C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. Blood. 2011;117(19):5178–88.
pubmed: 21292772
doi: 10.1182/blood-2010-08-304667
Davies LC, et al. Tissue-resident macrophages. Nat Immunol. 2013;14(10):986–95.
pubmed: 24048120
pmcid: 4045180
doi: 10.1038/ni.2705
Funes SC, et al. Implications of macrophage polarization in autoimmunity. Immunology. 2018;154(2):186–95.
pubmed: 29455468
pmcid: 5980179
doi: 10.1111/imm.12910
Poli A, et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–65.
pubmed: 19278419
pmcid: 2673358
doi: 10.1111/j.1365-2567.2008.03027.x
Giamarellos-Bourboulis EJ. Natural killer cells in sepsis: detrimental role for final outcome. Crit Care Med. 2014;42(6):1579–80.
pubmed: 24836809
doi: 10.1097/CCM.0000000000000352
Pastille E, et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J Immunol. 2011;186(2):977–86.
pubmed: 21160046
doi: 10.4049/jimmunol.1001147
Toliver-Kinsky TE, et al. Stimulation of hematopoiesis by the fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice. Infect Immun. 2003;71(6):3058–67.
pubmed: 12761083
pmcid: 155733
doi: 10.1128/IAI.71.6.3058-3067.2003
Benjamim CF, et al. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood. 2005;105(9):3588–95.
pubmed: 15604223
pmcid: 1895017
doi: 10.1182/blood-2004-08-3251
Lang JD, Matute-Bello G. Lymphocytes, apoptosis and sepsis: making the jump from mice to humans. Crit Care. 2009;13(1):109.
pubmed: 19216722
pmcid: 2688100
doi: 10.1186/cc7144
Hotchkiss RS, et al. Apoptosis in lymphoid and parenchymal cells during sepsis: findings in normal and T- and B-cell-deficient mice. Crit Care Med. 1997;25(8):1298–307.
pubmed: 9267941
doi: 10.1097/00003246-199708000-00015
Hotchkiss RS, et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol. 2005;174(8):5110–8.
pubmed: 15814742
doi: 10.4049/jimmunol.174.8.5110
Holtmeier W, Kabelitz D. Gammadelta T cells link innate and adaptive immune responses. Chem Immunol Allergy. 2005;86:151–83.
pubmed: 15976493
doi: 10.1159/000086659
Grimaldi D, et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med. 2014;40(2):192–201.
pubmed: 24322275
doi: 10.1007/s00134-013-3163-x
Tomasello E, Bedoui S. Intestinal innate immune cells in gut homeostasis and immunosurveillance. Immunol Cell Biol. 2013;91(3):201–3.
pubmed: 23478396
doi: 10.1038/icb.2012.85
Boomer JS, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594–605.
pubmed: 22187279
pmcid: 3361243
doi: 10.1001/jama.2011.1829
O’Sullivan ST et al. Major injury leads to predominance of the T helper-2 lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg, 1995. 222(4): p. 482 – 90; discussion 490-2.
Wu HP, et al. Associations of T helper 1, 2, 17 and regulatory T lymphocytes with mortality in severe sepsis. Inflamm Res. 2013;62(8):751–63.
pubmed: 23670410
pmcid: 3712133
doi: 10.1007/s00011-013-0630-3
Smeekens SP, et al. Functional genomics identifies type I interferon pathway as central for host defense against Candida albicans. Nat Commun. 2013;4:1342.
pubmed: 23299892
doi: 10.1038/ncomms2343
Venet F, et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med. 2009;35(4):678–86.
pubmed: 18946659
doi: 10.1007/s00134-008-1337-8
Monserrat J, et al. Early alterations of B cells in patients with septic shock. Crit Care. 2013;17(3):R105.
pubmed: 23721745
pmcid: 4056890
doi: 10.1186/cc12750
Suzuki K, et al. Reduced immunocompetent B cells and increased secondary infection in Elderly patients with severe Sepsis. Shock. 2016;46(3):270–8.
pubmed: 27172158
doi: 10.1097/SHK.0000000000000619
Czermak BJ, et al. Protective effects of C5a blockade in sepsis. Nat Med. 1999;5(7):788–92.
pubmed: 10395324
doi: 10.1038/10512
Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701–6.
pubmed: 22734959
pmcid: 3488423
doi: 10.1586/eri.12.50
Unnewehr H, et al. Changes and regulation of the C5a receptor on neutrophils during septic shock in humans. J Immunol. 2013;190(8):4215–25.
pubmed: 23479227
doi: 10.4049/jimmunol.1200534
Müller B, et al. Disordered calcium homeostasis of sepsis: association with calcitonin precursors. Eur J Clin Invest. 2000;30(9):823–31.
pubmed: 10998084
doi: 10.1046/j.1365-2362.2000.00714.x
Sayeed MM. Signaling mechanisms of altered cellular responses in trauma, burn, and sepsis: role of Ca2+. Arch Surg. 2000;135(12):1432–42.
pubmed: 11115349
doi: 10.1001/archsurg.135.12.1432
Collage RD, et al. Calcium supplementation during sepsis exacerbates organ failure and mortality via calcium/calmodulin-dependent protein kinase kinase signaling. Crit Care Med. 2013;41(11):e352–60.
pubmed: 23887235
doi: 10.1097/CCM.0b013e31828cf436
Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia in acutely ill patients in a medical intensive care setting. Am J Med. 1988;84(2):209–14.
pubmed: 3407650
doi: 10.1016/0002-9343(88)90415-9
Zivin JR, et al. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis. 2001;37(4):689–98.
pubmed: 11273867
doi: 10.1016/S0272-6386(01)80116-5
Brealey D, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet. 2002;360(9328):219–23.
pubmed: 12133657
doi: 10.1016/S0140-6736(02)09459-X
Larsen FJ, et al. Regulation of mitochondrial function and energetics by reactive nitrogen oxides. Free Radic Biol Med. 2012;53(10):1919–28.
pubmed: 22989554
doi: 10.1016/j.freeradbiomed.2012.08.580
Singer M. The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence. 2014;5(1):66–72.
pubmed: 24185508
doi: 10.4161/viru.26907
Biswas SK, et al. Macrophage polarization and plasticity in health and disease. Immunol Res. 2012;53(1):11–24.
pubmed: 22418728
doi: 10.1007/s12026-012-8291-9
Shapouri-Moghaddam A, et al. Macrophage plasticity, polarization, and function in health and disease. J Cell Physiol. 2018;233(9):6425–40.
pubmed: 29319160
doi: 10.1002/jcp.26429
Patel U, et al. Macrophage polarization in response to epigenetic modifiers during infection and inflammation. Drug Discovery Today. 2017;22(1):186–93.
pubmed: 27554801
doi: 10.1016/j.drudis.2016.08.006
Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol. 2011;11(11):723–37.
pubmed: 21997792
pmcid: 3422549
doi: 10.1038/nri3073
Feng L, et al. Pentamethoxyflavanone regulates macrophage polarization and ameliorates sepsis in mice. Biochem Pharmacol. 2014;89(1):109–18.
pubmed: 24607272
doi: 10.1016/j.bcp.2014.02.016
Xu X, et al. Inhibition of PTP1B promotes M2 polarization via MicroRNA-26a/MKP1 signaling pathway in murine macrophages. Front Immunol. 2019;10:1930.
pubmed: 31474996
pmcid: 6702542
doi: 10.3389/fimmu.2019.01930
Shakoory B, et al. Interleukin-1 receptor blockade is Associated with reduced mortality in Sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med. 2016;44(2):275–81.
pubmed: 26584195
pmcid: 5378312
doi: 10.1097/CCM.0000000000001402
Javaux C et al. Detection and Prediction of Macrophage Activation Syndrome in Still’s Disease. J Clin Med, 2021. 11(1).
Abdirakhmanova A, et al. Macrophage activation syndrome in Pediatric systemic lupus erythematosus: a systematic review of the diagnostic aspects. Front Med (Lausanne). 2021;8:681875.
pubmed: 34150813
doi: 10.3389/fmed.2021.681875
Natoli V, Rosina S, Ravelli A. Is Macrophage Activation Syndrome Kawasaki Disease Underrecognized? J Rheumatol. 2021;48(2):162–4.
pubmed: 32482652
Crayne CB, et al. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:119.
pubmed: 30774631
pmcid: 6367262
doi: 10.3389/fimmu.2019.00119
Chen S, et al. Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19. Front Immunol. 2023;14:1200289.
pubmed: 37483597
pmcid: 10358730
doi: 10.3389/fimmu.2023.1200289
Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like Syndrome: a distinct entity leading to early death in Sepsis. Front Immunol. 2019;10:55.
pubmed: 30766533
pmcid: 6365431
doi: 10.3389/fimmu.2019.00055
Leventogiannis K, et al. Toward personalized immunotherapy in sepsis: the PROVIDE randomized clinical trial. Cell Rep Med. 2022;3(11):100817.
pubmed: 36384100
pmcid: 9729870
doi: 10.1016/j.xcrm.2022.100817
Kyriazopoulou E, et al. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis. BMC Med. 2017;15(1):172.
pubmed: 28918754
pmcid: 5603161
doi: 10.1186/s12916-017-0930-5
Nandy A, et al. Multiorgan dysfunction syndrome in sepsis: is macrophage activation syndrome secondary to infection? Eur J Rheumatol. 2021;8(2):89–92.
pubmed: 33226328
doi: 10.5152/eurjrheum.2020.20081
Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28(2):277–92.
pubmed: 24974063
pmcid: 4074772
doi: 10.1016/j.berh.2014.03.002
Shimizu M, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2020;18(1):2.
pubmed: 31924225
pmcid: 6954608
doi: 10.1186/s12969-020-0399-1
Otsuka R, Seino KI. Macrophage activation syndrome and COVID-19. Inflamm Regen. 2020;40:19.
pubmed: 32834892
pmcid: 7406680
doi: 10.1186/s41232-020-00131-w
McGonagle D, et al. The role of cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537.
pubmed: 32251717
pmcid: 7195002
doi: 10.1016/j.autrev.2020.102537
Sönmez HE, et al. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol. 2018;37(12):3329–35.
pubmed: 29663156
doi: 10.1007/s10067-018-4095-1
Ravelli A et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol, 2016. 68(3): pp. 566 – 76.
Schulert GS, Grom AA. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2015;66:145–59.
pubmed: 25386930
doi: 10.1146/annurev-med-061813-012806
Heaton DC, Moller PW. Still’s disease associated with coxsackie infection and haemophagocytic syndrome. Ann Rheum Dis. 1985;44(5):341–4.
pubmed: 2988465
pmcid: 1001643
doi: 10.1136/ard.44.5.341
McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. 2021;17(3):145–57.
pubmed: 33547426
pmcid: 7863615
doi: 10.1038/s41584-020-00571-1
Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset still’s disease. J Autoimmun. 2018;93:24–36.
pubmed: 30077425
doi: 10.1016/j.jaut.2018.07.018
Dhote R, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003;49(5):633–9.
pubmed: 14558048
doi: 10.1002/art.11368
Lin CI, et al. Clinical analysis of macrophage activation syndrome in pediatric patients with autoimmune diseases. Clin Rheumatol. 2012;31(8):1223–30.
pubmed: 22615046
doi: 10.1007/s10067-012-1998-0
Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis. J Pediatr. 1996;129(5):630–2.
pubmed: 8917224
doi: 10.1016/S0022-3476(96)70140-3
Hadchouel M, Prieur AM, Griscelli C. Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr. 1985;106(4):561–6.
pubmed: 3981309
doi: 10.1016/S0022-3476(85)80072-X
Mouy R, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr. 1996;129(5):750–4.
pubmed: 8917244
doi: 10.1016/S0022-3476(96)70160-9
Ravelli A, et al. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis successfully treated with cyclosporine. J Pediatr. 1996;128(2):275–8.
pubmed: 8636829
doi: 10.1016/S0022-3476(96)70408-0
Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis Annu Rev Pathol. 2018;13:27–49.
pubmed: 28934563
Ramos-Casals M, et al. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503–16.
pubmed: 24290661
doi: 10.1016/S0140-6736(13)61048-X
Bojan A, et al. Macrophage activation syndrome: a diagnostic challenge (review). Exp Ther Med. 2021;22(2):904.
pubmed: 34257717
pmcid: 8243343
doi: 10.3892/etm.2021.10336
Henter JI, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–31.
pubmed: 16937360
doi: 10.1002/pbc.21039
Fardet L, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–20.
pubmed: 24782338
doi: 10.1002/art.38690
Henter JI, et al. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918–22.
pubmed: 1954380
doi: 10.1182/blood.V78.11.2918.2918
Strippoli R, Caiello I, De Benedetti F. Reaching the threshold: a multilayer pathogenesis of macrophage activation syndrome. J Rheumatol. 2013;40(6):761–7.
pubmed: 23588947
doi: 10.3899/jrheum.121233
Giamarellos-Bourboulis EJ, Netea MG. Macrophage Activation Syndrome in Sepsis: Does It Exist and How to Recognize It? in Annual Update in Intensive Care and Emergency Medicine 2020, J.-L. Vincent, Editor. 2020, Springer International Publishing: Cham. pp. 261–269.
Kang R, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1–116.
pubmed: 25010388
doi: 10.1016/j.mam.2014.05.001
Lopez JA, et al. Rapid and unidirectional perforin pore delivery at the cytotoxic immune synapse. J Immunol. 2013;191(5):2328–34.
pubmed: 23885110
doi: 10.4049/jimmunol.1301205
Liu K, et al. Impaired macrophage autophagy increases the immune response in obese mice by promoting proinflammatory macrophage polarization. Autophagy. 2015;11(2):271–84.
pubmed: 25650776
pmcid: 4502775
doi: 10.1080/15548627.2015.1009787
Sun K, et al. Mitophagy in degenerative joint diseases. Autophagy. 2021;17(9):2082–92.
pubmed: 32967533
doi: 10.1080/15548627.2020.1822097
Ferro-Novick S, Reggiori F, Brodsky JL. ER-Phagy, ER homeostasis, and ER Quality Control: implications for Disease. Trends Biochem Sci. 2021;46(8):630–9.
pubmed: 33509650
pmcid: 8286283
doi: 10.1016/j.tibs.2020.12.013
Eapen VV et al. Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy. Elife, 2021. 10.
Yamada A, et al. FBXO2/SCF ubiquitin ligase complex directs xenophagy through recognizing bacterial surface glycan. EMBO Rep. 2021;22(11):e52584.
pubmed: 34515398
pmcid: 8567282
doi: 10.15252/embr.202152584
Chen D, et al. Activated autophagy of innate immune cells during the early stages of major trauma. Front Immunol. 2022;13:1090358.
pubmed: 36713435
doi: 10.3389/fimmu.2022.1090358
Luo Y, et al. Araloside C attenuates atherosclerosis by modulating macrophage polarization via Sirt1-mediated autophagy. Aging. 2020;12(2):1704–24.
pubmed: 31986489
pmcid: 7053643
doi: 10.18632/aging.102708
Sanjurjo L, et al. CD5L promotes M2 macrophage polarization through autophagy-mediated upregulation of ID3. Front Immunol. 2018;9:480.
pubmed: 29593730
pmcid: 5858086
doi: 10.3389/fimmu.2018.00480
Chen P, Cescon M, Bonaldo P. Autophagy-mediated regulation of macrophages and its applications for cancer. Autophagy. 2014;10(2):192–200.
pubmed: 24300480
doi: 10.4161/auto.26927
Yang M, et al. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol Cancer. 2014;13:43.
pubmed: 24580730
pmcid: 4015740
doi: 10.1186/1476-4598-13-43
Sun Y, et al. Beclin-1-Dependent Autophagy protects the Heart during Sepsis. Circulation. 2018;138(20):2247–62.
pubmed: 29853517
pmcid: 6274625
doi: 10.1161/CIRCULATIONAHA.117.032821
Liu Q, et al. Circulating mitochondrial DNA-triggered autophagy dysfunction via STING underlies sepsis-related acute lung injury. Cell Death Dis. 2021;12(7):673.
pubmed: 34218252
pmcid: 8254453
doi: 10.1038/s41419-021-03961-9
Hsiao HW, et al. The decline of autophagy contributes to proximal tubular dysfunction during sepsis. Shock. 2012;37(3):289–96.
pubmed: 22089196
doi: 10.1097/SHK.0b013e318240b52a
Kristiansen M, et al. Identification of the haemoglobin scavenger receptor. Nature. 2001;409(6817):198–201.
pubmed: 11196644
doi: 10.1038/35051594
Ravelli A et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis, 2016. 75(3): pp. 481-9.
Parodi A, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009;60(11):3388–99.
pubmed: 19877067
doi: 10.1002/art.24883
Brands X, et al. Plasma ferritin as marker of macrophage activation-like Syndrome in critically ill patients with Community-Acquired Pneumonia. Crit Care Med. 2021;49(11):1901–11.
pubmed: 33935163
doi: 10.1097/CCM.0000000000005072
Kotsaki A, et al. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol. BMJ Open. 2022;12(12):e067251.
pubmed: 36600424
pmcid: 9772655
doi: 10.1136/bmjopen-2022-067251
Carcillo JA, et al. A systemic inflammation mortality risk Assessment Contingency table for severe Sepsis. Pediatr Crit Care Med. 2017;18(2):143–50.
pubmed: 27941423
pmcid: 5291785
doi: 10.1097/PCC.0000000000001029
Rosário C, et al. The hyperferritinemic syndrome: macrophage activation syndrome, still’s disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013;11:185.
pubmed: 23968282
pmcid: 3751883
doi: 10.1186/1741-7015-11-185
Wang W, et al. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010;1800(8):760–9.
pubmed: 20304033
pmcid: 2893236
doi: 10.1016/j.bbagen.2010.03.011
Worwood M, et al. Assignment of human ferritin genes to chromosomes 11 and 19q13.3----19qter. Hum Genet. 1985;69(4):371–4.
pubmed: 3857215
doi: 10.1007/BF00291657
Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505–16.
pubmed: 11986201
doi: 10.1182/blood.V99.10.3505
Recalcati S, et al. New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. J Autoimmun. 2008;30(1–2):84–9.
pubmed: 18191543
doi: 10.1016/j.jaut.2007.11.003
Santambrogio P, et al. Human serum ferritin G-peptide is recognized by anti-L ferritin subunit antibodies and concanavalin-A. Br J Haematol. 1987;65(2):235–7.
pubmed: 3828232
Cohen LA, et al. Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway. Blood. 2010;116(9):1574–84.
pubmed: 20472835
doi: 10.1182/blood-2009-11-253815
Tran TN, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood. 1997;90(12):4979–86.
pubmed: 9389717
doi: 10.1182/blood.V90.12.4979
De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood. 2009;114(20):4546–51.
pubmed: 19671920
pmcid: 2777130
doi: 10.1182/blood-2009-05-224188
Hulet SW, et al. Oligodendrocyte progenitor cells internalize ferritin via clathrin-dependent receptor mediated endocytosis. J Neurosci Res. 2000;61(1):52–60.
pubmed: 10861799
doi: 10.1002/1097-4547(20000701)61:1<52::AID-JNR6>3.0.CO;2-T
Fisher J, et al. Ferritin: a novel mechanism for delivery of iron to the brain and other organs. Am J Physiol Cell Physiol. 2007;293(2):C641–9.
pubmed: 17459943
doi: 10.1152/ajpcell.00599.2006
Kalgaonkar S, Lönnerdal B. Receptor-mediated uptake of ferritin-bound iron by human intestinal Caco-2 cells. J Nutr Biochem. 2009;20(4):304–11.
pubmed: 18602806
doi: 10.1016/j.jnutbio.2008.04.003
Ruddell RG, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappab-regulated signaling in rat hepatic stellate cells. Hepatology. 2009;49(3):887–900.
pubmed: 19241483
doi: 10.1002/hep.22716
Morikawa K, Oseko F, Morikawa S. H- and L-rich ferritins suppress antibody production, but not proliferation, of human B lymphocytes in vitro. Blood. 1994;83(3):737–43.
pubmed: 8298135
doi: 10.1182/blood.V83.3.737.737
Hann HW, et al. Effects of isoferritins on human granulocytes. Cancer. 1989;63(12):2492–6.
pubmed: 2720599
doi: 10.1002/1097-0142(19890615)63:12<2492::AID-CNCR2820631222>3.0.CO;2-7
Broxmeyer HE, et al. Identification of leukemia-associated inhibitory activity as acidic isoferritins. A regulatory role for acidic isoferritins in the production of granulocytes and macrophages. J Exp Med. 1981;153(6):1426–44.
pubmed: 6972999
doi: 10.1084/jem.153.6.1426
Wu H, et al. Immune checkpoint molecule Tim-3 promotes NKT cell apoptosis and predicts poorer prognosis in Sepsis. Clin Immunol. 2023;254:109249.
pubmed: 36736642
doi: 10.1016/j.clim.2023.109249
Wei Z, et al. Alpha-lactose reverses liver injury via blockade of Tim-3-mediated CD8 apoptosis in sepsis. Clin Immunol. 2018;192:78–84.
pubmed: 29689313
doi: 10.1016/j.clim.2018.04.010
Li L, et al. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A. 2010;107(8):3505–10.
pubmed: 20133674
pmcid: 2840523
doi: 10.1073/pnas.0913192107
Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009;66(20):3241–61.
pubmed: 19484405
pmcid: 11115736
doi: 10.1007/s00018-009-0051-1
Zheng J, Conrad M. The metabolic underpinnings of Ferroptosis. Cell Metab. 2020;32(6):920–37.
pubmed: 33217331
doi: 10.1016/j.cmet.2020.10.011
Feng H, et al. Transferrin receptor is a specific ferroptosis marker. Cell Rep. 2020;30(10):3411–e34237.
pubmed: 32160546
pmcid: 7172030
doi: 10.1016/j.celrep.2020.02.049
Hines MR, et al. Consensus-based guidelines for the Recognition, diagnosis, and management of Hemophagocytic Lymphohistiocytosis in critically ill children and adults. Crit Care Med. 2022;50(5):860–72.
pubmed: 34605776
doi: 10.1097/CCM.0000000000005361
Knaak C, et al. Hemophagocytic Lymphohistiocytosis in critically ill patients. Shock. 2020;53(6):701–9.
pubmed: 31626037
doi: 10.1097/SHK.0000000000001454
Wafa A, et al. Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: a study of 20 Moroccan adult patients. Clin Rheumatol. 2022;41(7):2021–33.
pubmed: 35179662
doi: 10.1007/s10067-022-06055-9
Dulhunty JM, et al. Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. Anaesth Intensive Care. 2011;39(2):231–7.
pubmed: 21485671
doi: 10.1177/0310057X1103900212
Giamarellos-Bourboulis EJ, et al. THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT. Shock. 2023;59(3S):21–5.
pubmed: 36867758
doi: 10.1097/SHK.0000000000001955
Ates HC, et al. On-Site therapeutic drug monitoring. Trends Biotechnol. 2020;38(11):1262–77.
pubmed: 33058758
doi: 10.1016/j.tibtech.2020.03.001
Leow EH, et al. Critically Ill Children with Hemophagocytic Lymphohistiocytosis: a Case Series of 14 patients. J Pediatr Hematol Oncol. 2017;39(6):e303–6.
pubmed: 28697170
doi: 10.1097/MPH.0000000000000916
Buyse S, et al. Critical care management of patients with hemophagocytic lymphohistiocytosis. Intensive Care Med. 2010;36(10):1695–702.
pubmed: 20532477
doi: 10.1007/s00134-010-1936-z
Wittebole X, et al. Adjunctive therapies for severe sepsis. Int J Antimicrob Agents. 2008;32(Suppl 1):S34–8.
pubmed: 18715758
doi: 10.1016/j.ijantimicag.2008.06.005
Bossi G, et al. Efficacy of Anakinra on multiple coronary arteries aneurysms in an infant with recurrent Kawasaki Disease, complicated by macrophage activation syndrome. Children. 2022;9(5):672.
pubmed: 35626849
pmcid: 9139195
doi: 10.3390/children9050672
Yi G, et al. Case Report: Baricitinib as an alternative in the maintenance therapy for macrophage activation syndrome secondary to nodular panniculitis. Front Immunol. 2022;13:914265.
pubmed: 35874753
pmcid: 9298961
doi: 10.3389/fimmu.2022.914265
Wang R, et al. Short-term, low-dose etoposide in refractory adult-onset still’s disease-associated macrophage activation syndrome. Clin Rheumatol. 2022;41(9):2817–23.
pubmed: 35590113
doi: 10.1007/s10067-022-06184-1
Annane D, et al. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. BMJ. 2004;329(7464):480.
pubmed: 15289273
pmcid: 515196
doi: 10.1136/bmj.38181.482222.55
Annane D, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–71.
pubmed: 12186604
doi: 10.1001/jama.288.7.862
Sprung CL, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.
pubmed: 18184957
doi: 10.1056/NEJMoa071366
Marik PE, et al. Hydrocortisone, Vitamin C, and thiamine for the treatment of severe Sepsis and septic shock: a Retrospective before-after study. Chest. 2017;151(6):1229–38.
pubmed: 27940189
doi: 10.1016/j.chest.2016.11.036
Chang P, et al. Combined treatment with hydrocortisone, vitamin C, and thiamine for Sepsis and septic shock: a Randomized Controlled Trial. Chest. 2020;158(1):174–82.
pubmed: 32243943
doi: 10.1016/j.chest.2020.02.065
Moskowitz A, et al. Effect of ascorbic acid, corticosteroids, and thiamine on Organ Injury in septic shock: the ACTS Randomized Clinical Trial. JAMA. 2020;324(7):642–50.
pubmed: 32809003
pmcid: 7435341
doi: 10.1001/jama.2020.11946
Iglesias J, et al. Outcomes of metabolic resuscitation using ascorbic acid, thiamine, and glucocorticoids in the early treatment of Sepsis: the ORANGES Trial. Chest. 2020;158(1):164–73.
pubmed: 32194058
doi: 10.1016/j.chest.2020.02.049
Kato T, et al. Efficacy of ascorbic acid, thiamine, and hydrocortisone combination therapy: Meta-analysis of Randomized controlled trials. Vivo. 2023;37(3):1236–45.
doi: 10.21873/invivo.13200
Lu D, Mao W. Hydrocortisone combined with Vitamin C and thiamine in the treatment of Sepsis/Septic shock: a systematic review with Meta-Analysis and Trial Sequential Analysis. Clin Invest Med. 2023;46(1):E36–49.
pubmed: 36966386
doi: 10.25011/cim.v46i1.40275
Sun Y et al. HAT therapy for sepsis: a review of the therapeutic rationale and current clinical evaluation status. J Intensive Med, 2023.
Long Y, et al. Research progress on therapeutic effect and mechanism of hydrocortisone on sepsis. Cell Mol Biomedical Rep. 2023;3(3):122–9.
doi: 10.55705/cmbr.2023.377524.1090
Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med. 2001;345(10):747–55.
pubmed: 11547745
doi: 10.1056/NEJMra993360
Shankar-Hari M, et al. Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care. 2012;16(2):206.
pubmed: 22424150
pmcid: 3584720
doi: 10.1186/cc10597
Emmenegger U, Spaeth PJ, Neftel KA. Intravenous immunoglobulin for hemophagocytic lymphohistiocytosis? J Clin Oncol. 2002;20(2):599–601.
pubmed: 11786591
doi: 10.1200/JCO.2002.20.2.599
Larroche C, et al. Intravenously administered gamma-globulins in reactive hemaphagocytic syndrome. Multicenter study to assess their importance, by the immunoglobulins group of experts of CEDIT of the AP-HP. Ann Med Interne (Paris). 2000;151(7):533–9.
pubmed: 11139652
Knaak C, et al. Treatment and mortality of Hemophagocytic Lymphohistiocytosis in adult critically ill patients: a systematic review with pooled analysis. Crit Care Med. 2020;48(11):e1137–46.
pubmed: 32947471
doi: 10.1097/CCM.0000000000004581
La Rosée P, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465–77.
pubmed: 30992265
doi: 10.1182/blood.2018894618
Turgeon AF, et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007;146(3):193–203.
pubmed: 17283351
doi: 10.7326/0003-4819-146-3-200702060-00009
Soares MO, et al. An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis. Health Technol Assess. 2012;16(7):1–186.
pubmed: 23177626
pmcid: 4781633
doi: 10.3310/hta16070
Alejandria MM, et al. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;20139:pCd001090.
Arnold DD, Yalamanoglu A, Boyman O. Systematic review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-mediated disorders. Front Immunol. 2022;13:888392.
pubmed: 35874710
pmcid: 9296857
doi: 10.3389/fimmu.2022.888392
Naymagon L. Anakinra for the treatment of adult secondary HLH: a retrospective experience. Int J Hematol. 2022;116(6):947–55.
pubmed: 35948764
pmcid: 9365216
doi: 10.1007/s12185-022-03430-9
Demir F, Gürler E, Sözeri B. Efficacy of anakinra treatment in pediatric rheumatic diseases: our single-center experience. Archives Rheumatol. 2022;37(3):435–43.
doi: 10.46497/ArchRheumatol.2022.8998
Diorio C, et al. Anakinra utilization in refractory pediatric CAR T-cell associated toxicities. Blood Adv. 2022;6(11):3398–403.
pubmed: 35395068
pmcid: 9198909
doi: 10.1182/bloodadvances.2022006983
Cavalli G, Dinarello CA. Anakinra Therapy for Non-cancer Inflammatory diseases. Frontiers in Pharmacology; 2018. p. 9.
Amikishiyev S, et al. POS1216 Potential predictors of outcome for anakinra treatment in COVID-19 patients with macrophage activation syndrome. Ann Rheum Dis. 2022;81(Suppl 1):937.
doi: 10.1136/annrheumdis-2022-eular.1637
Huet T, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol. 2020;2(7):e393–400.
pubmed: 32835245
pmcid: 7259909
doi: 10.1016/S2665-9913(20)30164-8
Cavalli G, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2(6):e325–31.
pubmed: 32501454
pmcid: 7252085
doi: 10.1016/S2665-9913(20)30127-2
Aouba A, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020;79(10):1381–2.
pubmed: 32376597
doi: 10.1136/annrheumdis-2020-217706
Kostik MM, et al. Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis. Front Pediatr. 2022;10:894846.
pubmed: 35967555
pmcid: 9366524
doi: 10.3389/fped.2022.894846
Gezgin Yıldırım D, et al. Recurrent macrophage activation syndrome due to hyperimmunoglobulin D syndrome: a case-based review. Clinical Rheumatology; 2022.
Ucciferri C, et al. Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020;2(8):e457–ee458.
pubmed: 32835251
pmcid: 7272172
doi: 10.1016/S2665-9913(20)30167-3
Landi L, et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep. 2020;10(1):21775.
pubmed: 33311551
pmcid: 7733468
doi: 10.1038/s41598-020-78492-y
Koritala T, et al. Infection risk with the use of interleukin inhibitors in hospitalized patients with COVID-19: a narrative review. Infez Med. 2021;29(4):495–503.
pubmed: 35146357
pmcid: 8805476
Sheng CC, et al. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: the three C study). Clin Cardiol. 2020;43(10):1055–63.
pubmed: 32830894
pmcid: 7461303
doi: 10.1002/clc.23451
Ao G, et al. The effect of canakinumab on clinical outcomes in patients with COVID-19: a meta-analysis. J Infect. 2022;84(6):834–72.
pubmed: 35301014
pmcid: 8920470
doi: 10.1016/j.jinf.2022.03.011
Grom AA, Horne A, De Benedetti F. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016;12(5):259–68.
pubmed: 27009539
pmcid: 5851441
doi: 10.1038/nrrheum.2015.179
Yamabe T, et al. Macrophage activation syndrome in patients with adult-onset still’s disease under tocilizumab treatment: a single-center observational study. Mod Rheumatol. 2022;32(1):169–76.
pubmed: 33719871
doi: 10.1080/14397595.2021.1899565
Naniwa T, et al. Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset still’s disease with a previous successful tocilizumab treatment. Mod Rheumatol Case Rep. 2021;5(2):360–4.
pubmed: 32883165
doi: 10.1080/24725625.2020.1818961
Vela D, et al. Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID-19; a systematic review and meta-analysis of randomized clinical trials. Br J Clin Pharmacol. 2022;88(5):1955–63.
pubmed: 34713921
doi: 10.1111/bcp.15124
Peng J, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol. 2022;32(3):e2295.
pubmed: 34558756
doi: 10.1002/rmv.2295
Veiga VC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.
pubmed: 33472855
doi: 10.1136/bmj.n84
Marino A, et al. Sarilumab Administration in COVID-19 patients: Literature Review and considerations. Infect Disease Rep. 2022;14(3):360–71.
doi: 10.3390/idr14030040
Sheng F, et al. Interleukin 6 receptor inhibitor tocilizumab suppresses cytokine expression, inflammasome activation and phagocytosis in a cell model of sepsis. Pharmazie. 2016;71(11):636–9.
pubmed: 29441967
Hatterer E, et al. P156 investigating the novel mechanism of action for NI-0501, a human interferon gamma monoclonal antibody. Cytokine. 2012;59(3):570.
doi: 10.1016/j.cyto.2012.06.257
De Benedetti F, et al. OP0193 Efficacy and safety of emapalumab, an anti-interferon gamma monoclonal antibody, in patients with Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA) who had failed high-dose glucocorticoids. Ann Rheum Dis. 2022;81(Suppl 1):128.
doi: 10.1136/annrheumdis-2022-eular.803
Rainone M, et al. Interferon-γ blockade in CART-cell therapy-associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis. Blood Adv; 2022.
Leentjens J, et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med. 2012;186(9):838–45.
pubmed: 22822024
doi: 10.1164/rccm.201204-0645OC
Gillard L et al. JAK inhibitors in difficult-to-treat adult-onset still’s disease and systemic-onset juvenile idiopathic arthritis. Rheumatology, 2022.
Keenan C, Nichols KE, Albeituni S. Use of the JAK inhibitor ruxolitinib in the treatment of Hemophagocytic Lymphohistiocytosis. Front Immunol. 2021;12:614704.
pubmed: 33664745
pmcid: 7923355
doi: 10.3389/fimmu.2021.614704
Levy O et al. Ruxolitinib for Refractory Macrophage Activation Syndrome Complicating Adult-Onset Still’s Disease. Eur J Rheumatol, 2022.
Cao Y, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial. J Allergy Clin Immunol. 2020;146(1):137–e1463.
pubmed: 32470486
pmcid: 7250105
doi: 10.1016/j.jaci.2020.05.019
Rein L, et al. Randomized Phase 3 Trial of Ruxolitinib for COVID-19-Associated Acute Respiratory Distress Syndrome. Crit Care Med. 2022;50(12):1701–13.
pubmed: 36226977
pmcid: 9668361
doi: 10.1097/CCM.0000000000005682
Han MK, et al. Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Rheumatol. 2022;4(5):e351–61.
pubmed: 35368384
pmcid: 8963773
doi: 10.1016/S2665-9913(22)00044-3
Liu JM, Chi J. Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis? Exp Biol Med (Maywood). 2022;247(4):330–7.
pubmed: 35068219
doi: 10.1177/15353702211068840
Berlot G, et al. The techniques of blood purification in the treatment of Sepsis and other Hyperinflammatory conditions. J Clin Med. 2023;12. https://doi.org/10.3390/jcm12051723 .
Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care. 2011;15(1):205.
pubmed: 21371356
pmcid: 3222040
doi: 10.1186/cc9411
Monard C, Rimmelé T, Ronco C. Extracorporeal blood purification therapies for Sepsis. Blood Purif. 2019;47(Suppl 3):2–15.
doi: 10.1159/000499520
Hoffmann JN, et al. Effect of hemofiltration on hemodynamics and systemic concentrations of anaphylatoxins and cytokines in human sepsis. Intensive Care Med. 1996;22(12):1360–7.
pubmed: 8986487
doi: 10.1007/BF01709552
Hawchar F et al. The potential role of extracorporeal cytokine removal in hemodynamic stabilization in hyperinflammatory shock. Biomedicines, 2021. 9(7).
Tan HK, Hart G. Plasma filtration. Ann Acad Med Singap. 2005;34(10):615–24.
pubmed: 16382247
Bauer PR, et al. Plasma exchange in the intensive care unit: a narrative review. Intensive Care Med. 2022;48(10):1382–96.
pubmed: 35960275
pmcid: 9372988
doi: 10.1007/s00134-022-06793-z
Ankawi G, et al. Extracorporeal techniques for the treatment of critically ill patients with sepsis beyond conventional blood purification therapy: the promises and the pitfalls. Crit Care. 2018;22(1):262.
pubmed: 30360755
pmcid: 6202855
doi: 10.1186/s13054-018-2181-z
Morgera S, et al. Intermittent high permeability hemofiltration in septic patients with acute renal failure. Intensive Care Med. 2003;29(11):1989–95.
pubmed: 12955174
doi: 10.1007/s00134-003-2003-9
Honoré P, Joannes-Boyau O, Kotulak T. Report of the working party on high volume hemofiltration including definitions and classification. in Proc 2nd Czech Conference on Critical Care Nephrology, Pardubice, Czech Republic. 2007.
Grootendorst AF, et al. High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med. 1992;18(4):235–40.
pubmed: 1430589
doi: 10.1007/BF01709839
Li CM, et al. Continuous veno-venous haemofiltration attenuates myocardial mitochondrial respiratory chain complexes activity in porcine septic shock. Anaesth Intensive Care. 2007;35(6):911–9.
pubmed: 18084982
doi: 10.1177/0310057X0703500609
Bellomo R, et al. The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med. 2000;161(5):1429–36.
pubmed: 10806135
doi: 10.1164/ajrccm.161.5.9809127
Lee PA, et al. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med. 1993;21(6):914–24.
pubmed: 8504662
doi: 10.1097/00003246-199306000-00022
Cole L, et al. High-volume haemofiltration in human septic shock. Intensive Care Med. 2001;27(6):978–86.
pubmed: 11497156
doi: 10.1007/s001340100963
Cornejo R, et al. High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med. 2006;32(5):713–22.
pubmed: 16550372
doi: 10.1007/s00134-006-0118-5
Honore PM, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med. 2000;28(11):3581–7.
pubmed: 11098957
doi: 10.1097/00003246-200011000-00001
Oudemans-van Straaten HM, et al. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med. 1999;25(8):814–21.
pubmed: 10447538
doi: 10.1007/s001340050957
Piccinni P, et al. Early isovolaemic haemofiltration in oliguric patients with septic shock. Intensive Care Med. 2006;32(1):80–6.
pubmed: 16328222
doi: 10.1007/s00134-005-2815-x
Ratanarat R, et al. Pulse high-volume haemofiltration for treatment of severe sepsis: effects on hemodynamics and survival. Crit Care. 2005;9(4):R294–302.
pubmed: 16137340
pmcid: 1269433
doi: 10.1186/cc3529
Breilh D, et al. Pharmacokinetics and pharmacodynamics of anti-infective agents during continuous veno-venous hemofiltration in critically ill patients: lessons learned from an ancillary study of the IVOIRE trial. J Translational Intern Med. 2019;7(4):155–69.
doi: 10.2478/jtim-2019-0031
Bellomo R, et al. High protein intake during continuous hemodiafiltration: impact on amino acids and nitrogen balance. Int J Artif Organs. 2002;25(4):261–8.
pubmed: 12027135
doi: 10.1177/039139880202500403
Rimmelé T, et al. L’hémofiltration en cascade: principe, premières données expérimentales. Ann Françaises d’Anesthésie et de Réanimation. 2009;28(3):249–52.
doi: 10.1016/j.annfar.2009.01.003
Therapeutic Modulation of the Host Defense by Hemoadsorption with CytoSorb
Rademacher JG, et al. Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic stem cell transplantation. J Artif Organs. 2021;24(3):402–6.
pubmed: 33459910
pmcid: 8380562
doi: 10.1007/s10047-020-01244-2
Bottari G, et al. Hemoperfusion with CytoSorb to Manage Multiorgan Dysfunction in the Spectrum of Hemophagocytic Lymphohistiocytosis Syndrome in critically Ill Children. Blood Purif. 2022;51(5):417–24.
pubmed: 34344006
doi: 10.1159/000517471
Eden G, et al. Safety and efficacy of the Seraph
pubmed: 35715801
pmcid: 9205040
doi: 10.1186/s13054-022-04044-7
Winchester JF, et al. Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif. 2003;21(1):79–84.
pubmed: 12566666
doi: 10.1159/000067860
Cruz DN, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301(23):2445–52.
pubmed: 19531784
doi: 10.1001/jama.2009.856
Dellinger RP, et al. Effect of targeted polymyxin B hemoperfusion on 28-Day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES Randomized Clinical Trial. JAMA. 2018;320(14):1455–63.
pubmed: 30304428
pmcid: 6233793
doi: 10.1001/jama.2018.14618
Novelli G, et al. Early management of endotoxemia using the endotoxin activity assay and polymyxin B-based hemoperfusion. Contrib Nephrol. 2010;167:91–101.
pubmed: 20519903
doi: 10.1159/000315923
Kogelmann K, et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21(1):74.
pubmed: 28343448
pmcid: 5366999
doi: 10.1186/s13054-017-1662-9
Brouwer WP, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23(1):317.
pubmed: 31533846
pmcid: 6749645
doi: 10.1186/s13054-019-2588-1
Hawchar F, et al. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care. 2019;49:172–8.
pubmed: 30448517
doi: 10.1016/j.jcrc.2018.11.003
Schultz P, et al. High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: a retrospective cohort study. J Crit Care. 2021;64:184–92.
pubmed: 33962219
doi: 10.1016/j.jcrc.2021.04.011
Scharf C, et al. Can the cytokine adsorber CytoSorb(
pubmed: 34292421
pmcid: 8295971
doi: 10.1186/s13613-021-00905-6
Wendel Garcia PD, et al. Cytokine adsorption in severe, refractory septic shock. Intensive Care Med. 2021;47(11):1334–6.
pubmed: 34471938
pmcid: 8409473
doi: 10.1007/s00134-021-06512-0
Supady A, Brodie D, Wengenmayer T. Extracorporeal haemoadsorption: does the evidence support its routine use in critical care? Lancet Respir Med. 2022;10(3):307–12.
pubmed: 34921755
doi: 10.1016/S2213-2600(21)00451-3
Ruiz-Rodríguez JC, et al. Case report: cytokine hemoadsorption in a case of hemophagocytic lymphohistiocytosis secondary to extranodal NK/T-cell lymphoma. Front Med (Lausanne). 2022;9:925751.
pubmed: 36045925
doi: 10.3389/fmed.2022.925751
Ceruti S, et al. Hemoadsorption Treatment with CytoSorb
Jarczak D, et al. Effect of Hemadsorption Therapy in critically ill patients with COVID-19 (CYTOCOV-19): a prospective Randomized Controlled Pilot Trial. Blood Purification; 2022.
Paul R, Aleem M, Gorla N. CytoSorb
Broman ME, et al. Endotoxin and cytokine reducing properties of the oXiris membrane in patients with septic shock: a randomized crossover double-blind study. PLoS ONE. 2019;14(8):e0220444.
pubmed: 31369593
pmcid: 6675097
doi: 10.1371/journal.pone.0220444
Feng J, et al. Effect of CRRT with oXiris filter on hemodynamic instability in surgical septic shock with AKI: a pilot randomized controlled trial. Int J Artif Organs. 2022;45(10):801–8.
pubmed: 35864718
doi: 10.1177/03913988221107947
Zhou Y, et al. Application of Oxiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: a single-centre experience in China. Front Public Health. 2022;10:1012998.
pubmed: 36249210
pmcid: 9557776
doi: 10.3389/fpubh.2022.1012998
Premužić V, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther Apher Dial. 2022;26(2):316–29.
pubmed: 34486793
doi: 10.1111/1744-9987.13730
Villa G, et al. Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study. Crit Care. 2020;24(1):605.
pubmed: 33046113
pmcid: 7549343
doi: 10.1186/s13054-020-03322-6
Li Y, et al. Effect of continuous renal replacement therapy with the oXiris Hemofilter on critically ill patients: a narrative review. J Clin Med. 2022;11. https://doi.org/10.3390/jcm11226719 .
Seffer MT, et al. Staphylococcus aureus binding to Seraph
pubmed: 36930680
pmcid: 10022791
doi: 10.1371/journal.pone.0283304
Chen Y, et al. Efficacy of plasma exchange on top of standard immunosuppressive therapy in adult autoimmune inflammatory rheumatic diseases-associated macrophage activation syndrome, a single center real-world analysis. Semin Arthritis Rheum. 2022;55:152043.
pubmed: 35696776
doi: 10.1016/j.semarthrit.2022.152043
Yuan YH, et al. Efficacy of plasma exchange in children with severe hemophagocytic syndrome: a prospective randomized controlled trial. Zhongguo Dang Dai Er Ke Za Zhi. 2022;24(3):249–54.
pubmed: 35351253
Stahl K, et al. Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022;26(1):134.
pubmed: 35551628
pmcid: 9097091
doi: 10.1186/s13054-022-04003-2
David S, et al. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med. 2021;47(3):352–4.
pubmed: 33471132
pmcid: 7816555
doi: 10.1007/s00134-020-06339-1
Faqihi F, et al. Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial. Int J Antimicrob Agents. 2021;57(5):106334.
pubmed: 33838224
pmcid: 8024223
doi: 10.1016/j.ijantimicag.2021.106334
Arulkumaran N, et al. Plasma exchange for COVID-19 thrombo-inflammatory disease. eJHaem. 2021;2(1):26–32.
pubmed: 33363289
doi: 10.1002/jha2.140
Gucyetmez B, et al. Therapeutic plasma exchange in patients with COVID-19 pneumonia in intensive care unit: a retrospective study. Crit Care. 2020;24(1):492.
pubmed: 32771054
pmcid: 7414262
doi: 10.1186/s13054-020-03215-8
Khamis F, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214–8.
pubmed: 32585284
pmcid: 7308750
doi: 10.1016/j.ijid.2020.06.064
Faqihi F, et al. Therapeutic plasma exchange in adult critically ill patients with life-threatening SARS-CoV-2 disease: a pilot study. J Crit Care. 2020;60:328–33.
pubmed: 32763058
pmcid: 9629267
doi: 10.1016/j.jcrc.2020.07.001
Hashemian SM, et al. Plasmapheresis reduces cytokine and immune cell levels in COVID-19 patients with acute respiratory distress syndrome (ARDS). Pulmonology. 2021;27(6):486–92.
pubmed: 33358260
doi: 10.1016/j.pulmoe.2020.10.017
Jaiswal V, et al. Therapeutic plasma exchange followed by convalescent plasma transfusion in critical COVID-19—An exploratory study. Int J Infect Dis. 2021;102:332–4.
pubmed: 33157287
doi: 10.1016/j.ijid.2020.10.085
Morath C, et al. Plasma exchange in critically ill COVID-19 patients. Crit Care. 2020;24(1):481.
pubmed: 32753056
pmcid: 7399583
doi: 10.1186/s13054-020-03171-3
Fernandez J, et al. Plasma exchange: an effective rescue therapy in critically ill patients with coronavirus disease 2019 infection. Crit Care Med. 2020;48(12):e1350–5.
pubmed: 32833695
pmcid: 7493773
doi: 10.1097/CCM.0000000000004613
Keith P, et al. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Crit Care. 2020;24(1):128.
pubmed: 32241301
pmcid: 7117947
doi: 10.1186/s13054-020-2836-4
Ronco C, et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med. 2002;30(6):1250–5.
pubmed: 12072677
doi: 10.1097/00003246-200206000-00015
Formica M, et al. Hemodynamic response to coupled plasmafiltration-adsorption in human septic shock. Intensive Care Med. 2003;29(5):703–8.
pubmed: 12665998
doi: 10.1007/s00134-003-1724-0
Cesano G, et al. [Treatment of septic shock with the use of CPFA (associated plasma filtration and adsorption): impact on hemodynamics monitored with PiCCO ]. G Ital Nefrol. 2003;20(3):258–63.
pubmed: 12881848
Hu D, et al. Effects of coupled plasma filtration adsorption on septic patients with multiple organ dysfunction syndrome. Ren Fail. 2012;34(7):834–9.
pubmed: 22607100
doi: 10.3109/0886022X.2012.684553
Franchi M, et al. Coupled plasma filtration adsorption improves hemodynamics in septic shock. J Crit Care. 2016;33:100–5.
pubmed: 26975736
doi: 10.1016/j.jcrc.2016.02.005
Livigni S, et al. Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: a multicenter randomised controlled clinical trial. BMJ Open. 2014;4(1):e003536.
pubmed: 24401721
pmcid: 3902195
doi: 10.1136/bmjopen-2013-003536
Garbero E, et al. High dose coupled plasma filtration and adsorption in septic shock patients. Results of the COMPACT-2: a multicentre, adaptive, randomised clinical trial. Intensive Care Med. 2021;47(11):1303–11.
pubmed: 34601619
doi: 10.1007/s00134-021-06501-3
Giménez-Esparza C, et al. The premature closure of ROMPA clinical trial: mortality reduction in septic shock by plasma adsorption. BMJ Open. 2019;9(12):e030139.
pubmed: 31796477
pmcid: 6924739
doi: 10.1136/bmjopen-2019-030139